thank time us. for you to and join the morning, Good taking
of you year specialized insulin Whether With the XXXX, care every diabetes newly XXXth to towards this mission a to device delivery while with a year and convenient as diagnosed, life-changing comfortable transitioning possible our of through make journey deliver therapy, innovation. the diabetes person day of new new experience are or marked our the solutions. better line of advancing generation in introduction is first as to a
been touch living our delivery in XX living over of at estimated And with for million is delivery insulin we life with and people global products, team. of we through everything and make years. the XXX drives one We diabetes our an diabetes providing have people is insulin developing nearly better countries, solutions what that the core leaders for do in XXX
to Turning year for our strategic priorities XXXX. fiscal
developed core to base position leader our and forward, the for priorities decision-making independent continue that X be as served seeking for our insulin injection had our most in position parent risk independent manner well company; X an opportunities. the finally, growth of devices; separating program thoughtful additional M&A insulin driving our we in our focused and us ourselves that notably since global maintaining is while business for pump actions a we on priorities former as mitigate from our on partnership focused being in strategic same patch they strengthening category company. and foundation have the We around the an as and success will These have investing remaining company include, and became as market type to
made very in that pleased we've of with in We areas. each these determination the a progress these and of are with objectives, urgency advancing sense and I'm
quarter first highlights. some to Turning
we and and view to delivering made in impacts communities our governance First, in the XXXX with progress broader business environmental, we develop and summary towards policies published report operate. a strategy commitment social our which This our including the a establishing responsibly solutions our ESG our that to we provides products underscore and XXXX of how systems report.
value the acceptance ATTD to believe Next, for recognition, the in treatments post conference gain diabetes at embecta that and upcoming March. of team's abstracts presentations technologies for as presentation the or advanced posters X these to leading continue We the benefit using adults hard work a like X greater in patients facilitate diabetes person health type would insulin a validate for resulting our and full potentially that reservoir with larger economic payers. a benefit single proposition a days a more pump and X to
in with symposium host on for diabetes potential insulin is with These and around the to pump type about embecta patients objectives By X are our the at care. type personalized of potential supporting set Additionally, to insulin excited educational improvements for X this diabetes. symposium, therapy and an focuses unlocking helping pumps diabetes decision-making industry-sponsored align innovation care. for form commitment we advance ATTD
implementation During services capabilities and separation the approximately the of our for new and our our our revenue facility programs U.S. operationalizing QX, within XX% advanced we ERP while Canadian network the shared and markets. system also of the manufacturing completing also U.S. by serving base notably distribution
being the are loop that specifically I'll the development about more these a insulin X FDA. our of in of application open premarket including terms filing in the patch progress for following of share patch slides. our significant insulin type the made of with we developed the market, latter XXX(k) version for accomplishments the Furthermore, pumps pump
results, results we these our the based the for the And that with during financial first solid on for year, per and guidance outlook led Finally, our internal quarter, exceeded raising execution coupled share. adjusted our earnings ranges of revenue financial are remainder to expectations.
into a we I the separation our detail would more of made advancements get bit regarding efforts. to like terms in Next,
just during risks. and adopted shared and phased we mitigate QX, implementation approach implementation programs, have These significant network. the separation As global team complex ERP are the a capabilities system, to our I our distribution mentioned, progress made in services of
shared distribution markets. the capabilities we implemented ERP and a logistics services Canadian our support today, have of system operationalized As to and U.S. and and new network
we China addition, are X our Nebraska, Suzhou, own In of implemented our manufacturing Holdrege, in X which and ERP plants.
markets as processes as well our Ireland. plant additional fiscal we remaining systems, in During second capabilities quarter, our to manufacturing our implement plan at and in
anticipate platform. We our than anticipate few we of the quarter, of a on X revenue in more shared our XX% ERP jurisdictions by own of locations fiscal having and excluding and quarters. manufacturing those second service implementation the base of relevant our our closing our in deferred markets, ERP system within all capabilities slightly all As such, end
would additional letter enable securing markets a from the from limited our To distribution ERP phased upon of certain contingent private extension, fiscal solution, and facilitate provide TSAs to to early XXXX. capabilities, specific of the us TSAs This a BD an year extend network for implementation IRS. extension agreements agreed limited ruling requested set for shared had and ruling services related we BD. until
and we continue as integrate exert with own BD to to we and efforts will processes. mitigate been from the risks our the have away substantial and and with associated transition company, TSAs Throughout potential systems disruptions implement
of While we successful specific we complexities navigate in systems generally standing the product disruptions and countries our major all have concurrently registrations, avoiding disruptions, at up there been sales while capabilities. licenses other and as temporary necessary a is of securing own possibility requirements
China already ultimately and report legal to transfer, we've entity and production steps is in entity prior other to calls, we execution. completed embecta. previously in manufacturing was that we from on that anticipate has domestic our Lastly, had significant years order in our process products previous and which fiscal expectations. commented in pleased I planning culminates and mentioned line earnings BD the resuming for We the for with process legal the for had to our as China Chinese demerger am is have transfer Suzhou, completed a accomplishment This entity quarter, we this several spanned market in export second a by markets. plant manufacturing that our to that team important
Turning version XXX(k) of to for to announced the the our we open This a program. loop milestone pump patch ago, our month in insulin program. patch insulin of the FDA. marks submission our the critical application A pump
and the through we are to the forward review have look filing this working to We with FDA pleased process. complete,
an This versions. are streamline also The platform our the targeted also us type be X should users. diabetes. patch across use individuals our We who allow insulin type same pump for is of expected development both across to have is X a pump hardware for substantially and addressing by the need open-loop pump a for that development patch closed-loop continuing to open-loop while market potential closed-loop pump tailored
reservoir considering daily. that crucial feature noteworthy is up accommodating up our typically of type believe is of pumps insulin to insulin to the size, X require units XXX One enhancement users units. this We XXX
that goal Our for supply cycle. that pump to needs wear of the our with indication aligns would is better an the have pumps users payers provide insulin and of replacement a appropriate X-day
open-loop submission development in are our pump our actively review, closed-loop also we FDA with Tidepool. collaboration advancing under While is
to them algorithm X FDA X Tidepool a working closed-loop a the already with into adapt are has type As and a their reminder, system. cleared type we by algorithm stand-alone
so that this made the pleased multiple and progress has are We also separation focus their program while far on maintaining proud with of activities. managed execute the to team
Now detail. first revenue performance in a let's more review bit quarter our
products an currency underlying During normalizing increase a a grew QX, contract on core we decline changes the non-diabetes basis. injection which basis and to currency that of for on X.X% constant manufacture generated we as-reported basis. a million, year-over-year X.X% X.X% revenue impact our represented of and the $XXX.X of constant an of BD, on business sell of When
FX the timing our in previously implementation aforementioned revenue orders QX due well our as to Our ERP of outlook. original tailwinds in our relation primarily exceeded as to communicated expectations, of advance customer
dollars As indicated half that that of the reported of our a dollar year generating revenue generated financial range when of reminder, percentage revenue year for slightly the XXXX we during midpoint approximately XXXX, And as-reported fiscal anticipated we that we annual the of our fiscal initial we XXXX. our a of first lower guidance first XX% as year. half provided during
ERP We our the we next quarters. expected quarter. continue unwind as within is we during system orders may QX case these see for mentioned earlier, I of as our additional positive implementing associated And second to from patterns such, some customer and timing fiscal as the And our plan while this capabilities will assumptions, the that within atypical impact do other fiscal occurred previously be markets to remain on noted the QX. few ordering during believe that
than results. Turning regions many U.S., in came we the back previously including Asia. to perspective, expected in our a and Canada QX geographic revenue better From
of decline represented year-over-year revenue totaled approximately the Regarding during X.X%. the U.S., which million, $XXX.X a quarter,
However, X.X%. contract our manufacturing when by headwinds, revenue U.S. injection business core normalizing for grew
to currency QX growth. $XXX.X international million, constant While during year-over-year revenue which totaled our equated flat
as turn Jake? That to in as And remarks. detail. more me results year let call my with Jake to prepared through financial the over guidance our well financial completes you that, quarter first the full updated take
